

## PERSONAL INFORMATION



**Evelina Tacconelli**

### PUBLICATIONS

Total number of publications in peer-review journals: **355**  
 Total number of citations: **24117** (Google Scholar)  
 H index: **75** (Google Scholar)

### FIELD OF INTEREST

Personalised medicine in infectious diseases - Antibiotic Stewardship - Diagnostic Stewardship – Antimicrobial resistance – AMR burden & epidemiology - Infection and Prevention Control – Infections in immunocompromised - COVID-19 - Evidence based medicine

## PROFESSIONAL EXPERIENCE

Since 5/2023	Chief Scientific Officer of ECRAID (European Clinical Research Alliance on Infectious Diseases), Utrecht, Netherlands
Since 10/ 2018	Head of Infectious Diseases Division, University of Verona; ID-CARE (Infectious Diseases Centre for TrAnslational REsearch), University of Verona
Since 10/ 2017	Full Professor, Infectious Diseases, University of Verona, Italy
Since 01/ 2021	Lecturer on Antimicrobial Resistance, DZIF Research Clinical Unit on healthcare associated infections and antimicrobial resistance, Infectious Diseases, Dept. Internal Medicine I, Tübingen University, Germany
2013 - 2020	Head of Division Of Infectious Disease, Dept Internal Medicine I, University Hospital Tübingen University, Germany
2012 – 2020	Head of the DZIF Research Clinical Unit on healthcare associated infections and antimicrobial resistance, Tübingen University, Germany
2012 – 2017	Full Professor, Infectious Diseases, University of Tübingen, Germany
2013 - 2018	Medical Director Comprehensive Center for infectious Diseases, University Hospital Tübingen
2013 - 2017	Head of Infectious Diseases Division, Internal Medicine I, University hospital, Tübingen
2003 - 2007	Lecturer on Medicine, Infectious Diseases, BIDMC and Harvard Medical School, Boston, USA
1999 - 2013	“Ricercatore”, Infectious Diseases, Catholic University, Rome, Italy
1997 - 1999	Infectious Diseases Specialist, Catholic University, Rome, Italy

## EDUCATION

09/1986 - 07/1992	Medical University (09/1986 –07/1992; 110/110 cum laude), Università Cattolica di Roma, Rome, Italy
09/1992 - 07/1996	Infectious Diseases Specialization (09/1992 –07/1996; 60/60 cum laude), Università Cattolica di Roma, Rome, Italy
09/1997- 06/1998	Master for Public Health Operators, Università la Sapienza, Rome, Italy

## SCHOLARSHIPS, AWARDS & PRICES

2020	“Lowbury Lecture 2020 for Excellence in Research in Prevention of Healthcare Associated Infections”, Hospital Infections Society, UK
2020	Profile eminent ID specialists: Lancet Infectious Disease Oct 2020: E Tacconelli, two viruses, two wars
2019	Listed in the publicly available database of 100,000 world’s top scientists (Ioannidis JPA, PLoS Biology 2019, <a href="https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000384">https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000384</a> )
2004	“Young Investigator Award for Clinical Microbiology and Infectious Diseases” European Society of Clinical Microbiology and Infectious Diseases
2003	“Young Investigator Award for the Study on Antibiotic Resistance”. Slovak Society of Chemotherapy, Slovakia
1998	“Junior Scholarship Award, University of London, for Curricula Studiorum and Abstract Presentation at 4 <sup>th</sup> International Congress on Drug Therapy in HIV Infection”, Glasgow.
1997	National scholarship for studies on AIDS, National Institute of Health, Italy

## EDITORIAL BOARDS (selection)

Since 2020	Senior Editor, Journal of Antimicrobial Chemotherapy
Since 2014	Scientific Committee, Clinical Microbiology and Infection
Since 2012	International Advisory Board, Lancet Infectious Diseases
2009 - 2019	Editorial Board, Journal of Antimicrobial Chemotherapy
2004 - 2013	Associated Editor, Clinical Microbiology and Infection

## SOCIETY & BOARD (selection)

Since 2023	<b>WHO R&amp;D of Antibacterial Treatments, expert member</b>
Since 2022	<b>Cohort Coordination Board (in collaboration with the European Commission), coordinator</b>
2022	<b>AMR stockpiling study group (public health with the European Commission), expert member</b>
Since 2021	<b>Coordinator of the national working group on improving antibiotics’ prescriptions, AIFA</b>
Since 2021	Veneto Region Working Group, Italy – Infectious Diseases Priority Plan, expert member
Since 2021	<b>Working Group for the coordination of the national plan on antimicrobial resistance (PNCAR, Minister of Health), expert member</b>
Since 2021	<b>ESCMID guidelines for the prevention of surgical site infections, Chairman</b>
Since 2021	<b>ESCMID guidelines for screening policies for healthcare workers to reduce the spread of SARS-CoV-2, Chairman</b>
Since 2021	Working group for the treatment of COVID-19 with monoclonal antibodies, Veneto Region, expert member
Since 2021	<b>Working group for the treatment of COVID-19 with monoclonal antibodies, Minister of Health, expert member</b>
Since 2020	Consultant for antibiotic therapy, Italian medicine Agency (AIFA)
Since 2020	Scientific and Technical Committee for controlling SARS-COV-2 infection of Veneto Region, expert member
Since 2020	<b>Working Group for appropriateness of hospital admission of patients with COVID-19 therapy (National Agency for Regional Health Services, AGENAS), expert member</b>
Since 2020	Scientific Committee for prevention and therapy of SARS-CoV-2 infection, Veneto Region, Italy, expert member

Since 2020	WHO Expert Group on Identifying Priority Fungal Pathogens, expert member
Since 2019	Regional Committee for the implementation of antimicrobial stewardship by national plan on antimicrobial resistance recommendations, Veneto Region, Chairman
Since 2019	<b>World Health Organisation (WHO) Essential Medicine List, Antibiotics Working Group, expert member</b>
Since 2019	<b>Selection Committee for the Department of Health and Social Care Antimicrobial Resistance Research Capital Funding Competition, NHS, United Kingdom (Capital: £32 million), Coordinator Deputy</b>
Since 2019	Master on Nursing Specialist on epidemiological surveillance and control of health-care associated infections, University of Verona, Italy, Coordinator
Since 2018	<b>Scientific Board of JPI-AMR (Joint Programming Initiative on Antimicrobial Resistance, European Commission), expert member</b>
Since 2018	Regional Therapeutic Committee, expert member, Veneto Region, Italy
Since 2018	Scientific Committee, expert member, IRCCS Sacro Cuore – Don Calabria', Negrar, Italy.
Since 2015	<b>Chair of EUCIC (European Committee of Infection Control)</b>
Since 2010	<b>ESCMID guidelines to control of hospital spreading of multidrug-resistant gram-negative bacteria, Chairman</b>
Since 2009	<b>European Center for Diseases Control (ECDC) Consultant for antibiotic stewardship and AMR</b>
2018 - 2019	<b>WHO Priority List of antimicrobial resistant bacteria for R&amp;D of effective antibiotics, Chairman</b>
2017 - 2019	<b>ESCMID guidelines Officer of Infectious Diseases and Clinical Microbiology</b>
2016 - 2019	<b>ESCMID guidelines for decolonisation of MDR gram-negative bacteria, Chairman</b>
2009 - 2017	<b>ESCMID Education Officer of Infectious Diseases and Clinical Microbiology</b>
2014 - 2017	<b>Clinical Advisory Board, HZI (Helmholtz Zentrum für Infektionsforschung, Germany), expert member</b>
2014 - 2016	Advisory Board, expert member, German Society for Infectious Diseases, DGI (Deutsche Gesellschaft für Infektiologie, Germany)
2009 - 2013	Study Group on Antibiotic Resistance in Hospitalised Patients, SIMIT, Chairman
2012 - 2013	<b>External Affairs Committee, expert member, SHEA (Society of Healthcare Epidemiologists of America)</b>
2012 - 2013	ESCMID Study Group on Infections in the Elderly (ESGIE), Chairman
2008 - 2012	ISC (International Society of Chemotherapy) Working Group on MRSA - Risk assessment, Chairman

#### RESEARCH PROJECTS (selection from 2010)

**Total budget coordinated: € 43.108.687 (last 5 years: €41.545.891)**

**Total site budget: € 17.426.145 (last 5 years: €15.863.349)**

Date	National and International Studies	Sponsor	Role - University / overall budget, €
March 2022	Update the 2017 WHO BPPL for research and development of new antibacterial treatments.	WHO	<b>Coordinator</b> €118.000
From 2021	Adaptive group sequential randomized control trial (Phase III) to assess the efficacy of mAb	AIFA	<b>Coordinator</b> € 839.095
From 2021	Vaccines And Monoclonal antibodies: Predicting the Impact on AMR and an Economic evaluation.	IMI	Partner € 280.275 / € 9.250.000
From 2021	AMMURAVID: Factorial, multicentre, randomized clinical trial of Remdesivir and immunotherapy	AIFA	<b>Coordinator</b>
From 2021	VACCELERATE-Italy: European Corona Vaccine Trial Accelerator Platform.	Horizon2020	<b>National Coordinator</b> € 92.361 / € 29.967.975
From 2021	ECRAID BASE: European Clinical Research Alliance on Infectious Diseases	Horizon2020	Partner € 999.815/ € 29.969.875

From 2021	REVERSE: Prevention and management tools for reducing antibiotic Resistance in high prevalence	Horizon2020	<b>National Coordinator</b> € 2.017.882 / € 13.953.194
From 2020	ORCHESTRA: Connecting European Cohorts to Increase Common and Effective Response to SARS.	Horizon2020	<b>Coordinator</b> € 2.204.998 / € 27.887.540
From 2020	WHO Solidarity Trial: international clinical trial to help find an effective treatment for COVID-19.	WHO	In-kind contribution
From 2020	ENACT: Alliance against COVID-19.	Fondazione CariVerona	WP leader € 886.234
From 2020	EU-RESPONSE: European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases.	Horizon2020	<b>National Coordinator</b> € 217.047 / €15.719.450
From 2020	SARS-CoV-2 Surveillance in school and public places.	CORIS Regione Veneto	Partner € 338.000
From 2019	Development of a web tool to perform surveillance connected to antibiotic prescription in hospital and community.	CORIS Regione Veneto	<b>Coordinator</b> € 210.000
From 2019	VALUE DX – : The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use.	IMI	WP leader € 83.705 / € 6.799.100
From 2019	Factors And Barriers for Preparation of a Phase 3 RCS with ExPEC10V in Adults Aged 60-85 Years With UTI.	IMI	Partner € 1.109.716 / € 83.033.010
2019	Systematic review to develop a WHO Index integrated in the AWARE index to measure optimal antibiotic usage	WHO	<b>Coordinator</b> € 21.000
2019	WHO Tender: Duration of antibiotic therapy to treat community acquired pneumonia.	WHO	<b>Coordinator</b> € 22.000
From 2019	DZIF-PREDICT Validation of the BLOOMY score for mortality.	DZIF	<b>Coordinator</b> € 89.900
2019-2022	COMBACTE-MAGNET Understanding of the epidemiology and clinical impact of CDI	IMI	Partner € 2.294.881 / € 75.340.000
2020- 2021	SENTINELLA: Rapid identification of SARS-CoV-2 in vulnerable population	Fondazione Veronese	<b>Coordinator</b> € 737.640
Since 2019	BIOSTEPS: Personalised surgical prophylaxis in pancreatic surgery in high AMR prevalence	AIFA	Partner € 100.000
2018-2021	Understanding and modelling reservoirs, vehicles and transmission of ESBL-Ent. in the community and LTCF.	Horizon 2020	WP leader € 680.000
2018-2020	Combination therapy to treat sepsis due to carbapenem-Resistant bacteria in adult and paediatric population	GARDP	<b>Coordinator</b> € 120.000
2015-2020	DZIF-R-Net Surveillance for antibiotic resistant infections	DZIF	Partner € 95.900
2012-2020	DZIF (German Center for Infectious Diseases Research) CT for research on prevention and treatment of HAIs	DZIF	<b>Coordinator</b> € 1.101.000
2018-2019	Increasing communication, awareness and data sharing in a global approach against resistance	JPI-AMR	In-kind contribution
2018-2019	GAP-One Project: “Global Antimicrobial resistance Platform for ONE Burden Estimates”.	JPI-AMR	In-kind contribution
2018-2019	ARCH Project: Bridging the gap between human and animal surveillance data, antibiotic policy, and stewardship. Design: Consensus-driven guidelines development and research priority setting.	JPI-AMR	<b>Coordinator</b> € 50.000
2016-2019	Surveillance of multidrug resistant bacteria in human and animal in Baden Württemberg	Baden-Württemb.	<b>Coordinator</b> € 340.000
2015-2019	DZIF-ABSOLUTE Antimicrobial stewardship to reduce resistance	DZIF	Partner

			€ 99.700
2015-2019	DZIF-BLOOMY Solution for the improvement of bloodstream infections	DZIF	<b>Coordinator</b> € 72.600
2017-2018	Burden of antibiotic resistant infection (GLASS initiative)	WHO	<b>Coordinator</b> € 35.000
2016-2018	IMI-2016-COMBACTE-MAGNET- ICU-ASPIRE	IMI	Partner € 89.000
2014-2018	DRIVE-AB (IMI-2014): "Driving reinvestment in R&D and appropriate usage of antibiotics	IMI	Partner € 373.600
2016-2017	Priority list for AMR pathogens for the R&D for new antibiotics.	WHO	<b>Coordinator</b> € 144.000
2012-2015	DZIF-ATHOS Antimicrobial stewardship in community and healthcare facilities.	DZIF	Partner € 63.000
2012-2015	DZIF- SPECTRUM- Risk factors for Clostridium difficile at hospital admission"	DZIF	Partner € 60.000
2012-2015	"Excellence in Research in Infectious Diseases", University of Tübingen.	EKUT	<b>Coordinator</b> € 240.000
2010-2014	SATURN: impact of specific antibiotic therapies on the prevalence of human host resistant bacteria.	FP7	WP leader € 848.000
2011-2013	Preserving old antibiotics for the future: assessment of clinical efficacy by a PK/P	FP7	Partner € 264.640
2010-2013	European Grant DG Sanco Implementing Strategic Bundles for Infection Prevention & Management	DG Sanco	Partner € 87.156

#### TEN SELECTED PUBLICATIONS:

1. Tacconelli E, et al. Development and validation of BLOOMY prediction scores for 14-day and 6-month mortality in hospitalized adults with bloodstream infections: a multicenter, prospective, cohort study. *Lancet Infect Dis* 2021, Dec 1-12 (Impact Factor 25,07)
2. Carrara E, .. Tacconelli E. ESCMID guidelines on testing for SARS-CoV-2 in asymptomatic individuals to prevent transmission in the health care setting. *Clin Microbiol Infect.* 2022 Feb (Impact Factor 8,06)
3. Tacconelli E, et al. Surveillance for control of antimicrobial resistance. *Lancet Infect Dis* 2017, Oct, 1-8 (Impact Factor 25,07)
4. Tacconelli E, et al. Discovery, research and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria. *Lancet Infect Dis.* 2018 Mar;18(3):318-327. (Impact Factor 25,07; **3150 citations**)
5. Savoldi A, ... Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-Analysis in World Health Organization Regions *J of Gastroenterology* 2018 (Impact Factor 22,6; 520 citations)
6. Tacconelli E et al. Fighting the enemy within. *Science* 2017 Feb 17;355(6326):689-690. (Impact Factor 13,08)
7. Baur D,... Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonization with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. *Lancet Infect Dis.* 2017 Sep;17(9):990-1001. (Impact Factor 25,07; citations 487)
8. Tacconelli E, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect.* 2014 Jan;20 Suppl 1:1-55. (Impact Factor 8,06; 660 citations)
9. Tacconelli E, et al. Rapid screening tests for methicillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. *Lancet Infect Dis.* 2009 Sep;9(9):546-54. (Impact Factor 25,07; citations 519)
10. Tacconelli E, et al. Preventing the influx of vancomycin-resistant enterococci into health care institutions, by use of a simple validated prediction rule. *Clin Infect Dis.* 2004 Oct 1;39(7):964-70. (Impact Factor 9,07)

Verona, 11/07/2023  
Evelina Tacconelli